Seeking Alpha

Ampio Pharmaceuticals (AMPE) receives FDA acceptance of a questionnaire that it plans to use in...

Ampio Pharmaceuticals (AMPE) receives FDA acceptance of a questionnaire that it plans to use in a pivotal trial in the U.S. for its Zertane treatment for premature ejaculation (PE). The testing will cost less than $4M. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|